• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by SWK Holdings Corporation (Amendment)

    11/23/21 4:42:56 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email
    SC 13D/A 1 d263981dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    Under the Securities Exchange Act of 1934

    (Amendment No. 13)*

     

     

    SWK HOLDINGS CORPORATION

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    78501P203

    (CUSIP Number)

    Marcus Pennington

    Carlson Capital, L.P.

    2100 McKinney Avenue

    Dallas, TX 75201

    (214) 932-9600

    with a copy to:

    Richard J. Birns, Esq.

    William B. Sorabella, Esq.

    Gibson, Dunn & Crutcher LLP

    200 Park Avenue

    New York, NY 10166

    (212) 351-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 23, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 78501P203    Page 2 of 11

     

      1.    

      Names of Reporting Persons

     

      Double Black Diamond Offshore Ltd.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      8,493,088 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      8,493,088 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,493,088 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      66.3%*

    14.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 3 of 11

     

      1.    

      Names of Reporting Persons

     

      Black Diamond Offshore Ltd.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      600,678 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      600,678 Shares

    11.     

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      600,678 Shares

    12.   

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.   

      Percent of Class Represented by Amount in Row (11)

     

      4.7%*

    14.   

      Type of Reporting Person (See Instructions)

     

      CO

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 4 of 11

     

      1.    

      Names of Reporting Persons

     

      Carlson Capital, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      9,093,766 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      9,093,766 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,093,766 Shares (includes warrant to purchase 100,000 Shares)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      71.0%*

    14.  

      Type of Reporting Person (See Instructions)

     

      PN; IA

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 5 of 11

     

      1.    

      Names of Reporting Persons

     

      Asgard Investment Corp. II

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      9,093,766 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      9,093,766 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,093,766 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      71.0%*

    14.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 6 of 11

     

      1.    

      Names of Reporting Persons

     

      Asgard Investment Corp.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      9,093,766 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      9,093,766 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,093,766 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      71.0%*

    14.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 7 of 11

     

      1.    

      Names of Reporting Persons

     

      Clint D. Carlson

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      9,093,766 Shares

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      9,093,766 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      9,093,766 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      71.0%*

    14.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    *

    The calculation is based on an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.


    CUSIP No. 78501P203    Page 8 of 11

     

    Explanatory Note

    This Amendment No. 13 (“Amendment No. 13”) amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2009 (the “Original Schedule 13D”), as amended by Amendment No. 1 to the Original Schedule 13D filed with the SEC on November 25, 2009 (“Amendment No. 1”), and as further amended by Amendment No. 2 to the Original Schedule 13D filed with the SEC on March 1, 2012 (“Amendment No. 2”), and as further amended by Amendment No. 3 to the Original Schedule 13D filed with the SEC on September 9, 2013 (“Amendment No. 3”), and as further amended by Amendment No. 4 to the Original Schedule 13D filed with the SEC on May 16, 2014 (“Amendment No. 4”), and as further amended by Amendment No. 5 to the Original Scheduled 13D filed with the SEC on June 23, 2014 (“Amendment No. 5”), and as further amended by Amendment No. 6 to the Original Schedule 13D filed with the SEC on July 16, 2014 (“Amendment No. 6”), and as further amended by Amendment No. 7 to the Original Schedule 13D filed with the SEC on August 19, 2014 (“Amendment No. 7”), and as further amended by Amendment No. 8 to the Original Schedule 13D filed with the SEC on December 8, 2014 (“Amendment No. 8”), and as further amended by Amendment No. 9 to the Original Schedule 13D filed with the SEC on March 30, 2018 (“Amendment No. 9), and as further amended by Amendment No. 10 to the Original Schedule 13D filed with the SEC on April 6, 2021 (“Amendment No. 10”), and as further amended by Amendment No. 11 to the Original Schedule 13D filed with the SEC on May 18, 2021 (“Amendment No. 11”), and as further amended by Amendment No. 12 to the Original Schedule 13D filed with the SEC on November 12, 2021 (“Amendment No. 12,” and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8, Amendment No. 9, Amendment No. 10, Amendment No. 11, Amendment No. 12 and this Amendment No. 13, the “Schedule 13D”), with respect to the shares of common stock (“Shares”), par value $0.001 per share, of SWK Holdings Corporation (the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 13 have the meanings set forth in the Schedule 13D. This Amendment No. 13 amends Items 4, 5, 6 and 7 as set forth below.

    Item 4. Purpose of Transaction

    The information previously provided in response to Item 4 is hereby amended and supplemented by adding the following information:

    On November 23, 2021, Carlson Capital delivered a letter (the “November 23 Letter”) to the members of the board of directors of the Issuer, pursuant to which Carlson Capital has proposed to acquire all issued and outstanding shares of the Issuer not already owned by Carlson Capital for a price of $19.00 per share, payable in cash (the “Proposed Transaction”).

    In connection with the Proposed Transaction, the Reporting Persons will seek to obtain access to, and review, additional due diligence materials from the Issuer and conduct discussions with the Issuer regarding the terms of the Proposed Transaction. The Reporting Persons may change the terms of the Proposed Transaction, determine to accelerate or terminate discussions with the Issuer with respect to the Proposed Transaction or alternative transactions, withdraw their offer to pursue the Proposed Transaction, take any action to facilitate or increase the likelihood of consummation of the Proposed Transaction, or change their intentions with respect to any such matters, in each case at any time and without prior notice, except for such notice as is required by applicable law. The Reporting Persons and their affiliates may, directly or indirectly, take such additional steps as they may deem appropriate to further the Proposed Transaction, including, without limitation, (x) engaging in discussions with other stockholders, potential sources of financing, advisors, and other relevant parties, and (y) entering into agreements, arrangements and understandings as may be appropriate in connection with the Proposed Transaction.

    The foregoing summary of the November 23 Letter is qualified in its entirety by reference to the full text of the November 23 Letter, a copy of which is attached hereto as Exhibit 20 and is incorporated by reference herein. The Proposed Transaction may result in one or more of the actions specified in clauses (i) through (ix) (as defined below), including an extraordinary corporate transaction involving the Issuer or any of its subsidiaries, a sale or transfer of a material amount of assets of the Issuer or its subsidiaries, a change in the board of directors or management of the Issuer or its subsidiaries, a material change in the present capitalization or dividend policy of the Issuer or other material change in the Issuer’s business or corporate structure. There can be no assurance as to the outcome of any discussions related to the Proposed Transaction or that the Proposed Transaction will be consummated.

    At the time of the filing of this Amendment No. 13, except as disclosed in this Schedule 13D, the Reporting Persons have no present plans in their capacity as stockholders which relate to or would result in (i) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (ii) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries, (iii) any change in the board of directors or management of the Issuer or any of its subsidiaries, (iv) any material change in the present capitalization or dividend policy of the Issuer, (v) any other material change in the Issuer’s business or corporate structure, (vi) changes in the Issuer’s charter or bylaws or other actions which may impede the acquisition of control of the Issuer by any person, (vii) causing a class of securities of the Issuer to be delisted from a national securities exchange or cease to be quoted in an inter-dealer quotation system of a registered national securities association, (viii) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (ix) any action similar to any of those described above (collectively, “clauses (i) through (ix)”). However, the Reporting Persons may, from time to time, engage in discussions, whether initiated by the Reporting Persons or another party, concerning proposals for transactions or other arrangements that may relate to or, if consummated, result in an event described in clauses (i) through (ix). The Reporting Persons may review and evaluate their investments in the Issuer at any time, whether in light of the discussions described in the immediately preceding sentence or otherwise, which may give rise to plans or proposals in addition to or in lieu of the Proposed Transaction that, if consummated, would result in one or more of the events described in clauses (i) through (ix).


    CUSIP No. 78501P203    Page 9 of 11

     

    Item 5. Interest in Securities of the Issuer

    Paragraphs (a) and (c) of Item 5 of the Schedule 13D are hereby amended and restated in their entirety as follows:

    (a) As of the close of business on November 23, 2021, the Reporting Persons beneficially owned an aggregate of 9,093,766 Shares, constituting approximately 71.0% of the Shares outstanding. The aggregate percentages of Shares reported in this Amendment No. 13 are based upon an aggregate number of 12,809,438 Shares outstanding as of November 8, 2021, as reported in the Issuer’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on November 12, 2021.

    (c) No transactions were effected by the Reporting Persons in the Shares since the filing of Amendment No. 12.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information previously provided in response to Item 6 is hereby amended and supplemented by adding the following information: Item 4 of this Amendment No. 13 is hereby incorporated by reference.

    Item 7. Materials to be Filed as Exhibits

    The information previously provided in response to Item 7 is hereby amended and supplemented by adding the following at the end thereof:

     

    Exhibit    Description
    20    Letter to Members of the Board of Directors of the Issuer, dated November 23, 2021


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 23, 2021

     

    DOUBLE BLACK DIAMOND OFFSHORE LTD.
    By:   Carlson Capital, L.P., its investment manager
    By:   Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

      Name: Clint D. Carlson
      Title: President
    BLACK DIAMOND OFFSHORE LTD.
    By:   Carlson Capital, L.P., its investment manager
    By:   Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

      Name: Clint D. Carlson
      Title: President
    CARLSON CAPITAL, L.P.
    By:   Asgard Investment Corp. II, its general partner
    By:  

    /s/ Clint D. Carlson

      Name: Clint D. Carlson
      Title: President


    SIGNATURES

     

    ASGARD INVESTMENT CORP. II
    By:  

    /s/ Clint D. Carlson

      Name: Clint D. Carlson
      Title: President
    ASGARD INVESTMENT CORP.
    By:  

    /s/ Clint D. Carlson

      Name: Clint D. Carlson
      Title: President

    /s/ Clint D. Carlson

    Clint D. Carlson
    Get the next $SWKH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT Staggs Joe David Jr exercised 33,750 shares at a strike of $11.22 and covered exercise/tax liability with 25,857 shares, increasing direct ownership by 7% to 123,766 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      4/17/25 4:34:14 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • PRESIDENT Staggs Joe David Jr was granted 36,700 shares, increasing direct ownership by 46% to 115,873 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:55 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Chief Financial Officer Rice Adam was granted 9,175 shares, increasing direct ownership by 151% to 15,247 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Financials

    Live finance-specific insights

    See more
    • SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

      Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

      11/14/24 4:15:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

      10/17/24 4:15:00 PM ET
      $BTCY
      $DERM
      $ELUT
      $ETON
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on SWK Holdings with a new price target

      Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      12/28/22 9:18:49 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Lake Street initiated coverage on SWK Holdings with a new price target

      Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      4/18/22 8:44:23 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      11/14/24 11:49:47 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

      SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

      10/25/24 4:05:56 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      2/14/24 2:14:12 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImpediMed Secures $15m Growth Capital Funding

      New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

      2/7/25 11:00:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.OriginationsIn November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share.In December, SWK closed an $8.0M senior secured term loan with Triple

      1/6/25 7:35:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    SEC Filings

    See more
    • SWK Holdings Corporation filed SEC Form 8-K: Other Events

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/19/25 8:47:29 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:23:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:22:48 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Appoints Chief Financial Officer

      Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

      7/8/24 5:00:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Stanley Black & Decker Appoints Chris Nelson Chief Operating Officer and Executive Vice President and President of Tools & Outdoor

      NEW BRITAIN, Conn., May 2, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK) today announced the appointment of Chris Nelson as Chief Operating Officer of the company, and Executive Vice President and President of Tools & Outdoor, effective June 14, 2023. Nelson joins Stanley Black & Decker from Carrier Corporation and brings more than 25 years of leadership experience in general management, product development and innovation, and growth transformation. Nelson will report to Donald Allan Jr., President and CEO of Stanley Black & Decker. He will assume the role of President, Tools & Outdoor, from current Acting Co-Presidents Robert Raff and John Wyatt. Raff will continue to serve as Chie

      5/2/23 4:36:00 PM ET
      $SWK
      $SWKH
      Industrial Machinery/Components
      Consumer Discretionary
      Diversified Financial Services
      Finance